Novo Nordisk's Ziltivekimab Fails ZEUS Phase 3 Trial, Triggering Largest Single-Day Stock Drop Since February 2026
核心洞察
Novo Nordisk's IL-6 inhibitor ziltivekimab failed to meet the primary endpoint of reducing major adverse cardiovascular events (MACE) in the ZEUS late-stage trial involving over 6,300 patients.
The drug reduced inflammation markers as expected but showed no meaningful reduction in cardiovascular death, non-fatal heart attack, or non-fatal stroke versus placebo.
NVO stock fell over 10% in its largest single-day drop since February 2026, ending a three-month winning streak, though analysts at Jefferies and Citi called the selloff excessive.
Novo Nordisk's experimental cardiovascular drug ziltivekimab failed to meet its primary endpoint in the pivotal ZEUS phase 3 trial, the company announced on July 31, sending shares down over 10% in the largest single-day decline since February 23, 2026. The outcome marks a significant setback in the Danish drugmaker's efforts to build a cardiovascular franchise beyond its dominant obesity and diabetes portfolio.
The ZEUS trial enrolled more than 6,300 patients with atherosclerotic cardiovascular disease (搜索), chronic kidney disease (搜索), and inflammation, testing once-monthly ziltivekimab against placebo on top of standard care. While the IL-6 inhibitor reduced inflammation markers as expected, it demonstrated no meaningful reduction in major adverse cardiovascular events (MACE)—a composite endpoint comprising cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.
Safety findings were generally comparable between the treatment and placebo arms, though serious infections occurred at a higher rate in patients receiving ziltivekimab.
Analyst Expectations and Market Reaction
The failure caught analysts off guard. Jefferies had estimated the MACE market opportunity at over $10 billion annually and noted before the results that the study would need to demonstrate at least a 20% risk reduction to support widespread clinical adoption. Goldman Sachs analysts had previously stated that a successful trial could have positioned ziltivekimab as the core of Novo Nordisk's cardiovascular disease franchise, reducing the company's heavy reliance on semaglutide-based products Ozempic and Wegovy.
Despite the disappointment, both Jefferies and Citi argued that the stock's sharp decline appeared excessive given ziltivekimab's relatively small share in Novo Nordisk's overall portfolio. Jefferies noted the result is "strategically negative because it deprives Novo Nordisk of a relatively reliable growth opportunity in the non-obesity field, and once again highlights the company's commercial execution in obesity as well as its current reliance on external innovation to drive growth."
Financial and Pipeline Implications
Novo Nordisk confirmed the trial outcome will trigger a non-cash impairment charge in the third quarter but leaves the company's adjusted operating profit outlook for 2026 unchanged. Two additional ziltivekimab trials—one in heart failure and another in post-heart attack patients—are continuing, with results expected in the first half of 2027.
Martin Holst Lange, Chief Scientific Officer at Novo Nordisk, addressed the setback: "While ziltivekimab did not achieve the major adverse cardiovascular event (MACE) benefit we expected, this does not change our strategic commitment to cardiovascular disease."
The failure increases pressure on Novo Nordisk to pursue acquisitions or advance other pipeline assets amid intensifying competition from Eli Lilly's tirzepatide products and ongoing pricing headwinds in the U.S. market. The company has guided for adjusted sales and operating profit declines of approximately 4-12% at constant exchange rates for 2026.
Regulatory Bright Spots
The pipeline disappointment was partially offset by positive regulatory developments earlier in July. On July 15, the European Commission granted marketing authorization for the Wegovy oral formulation, making it the first oral GLP-1 receptor agonist approved for weight management across the entire European Union. The approval, based on the OASIS clinical program in which the pill delivered approximately 17% mean weight loss versus roughly 3% with placebo, marked the fifth regulatory nod following approvals in the US, UK, UAE, and Bahrain.
The same day, the EC also approved the higher-dose Wegovy 7.2 mg injection in a single-dose pen, which demonstrated near 21% mean weight loss in clinical studies.
Competitive Dynamics and Upcoming Catalysts
July also saw heightened competitive tensions, with Novo Nordisk filing a lawsuit against Eli Lilly on July 21, alleging misleading national advertising for Lilly's GLP-1 drugs that used outdated or mismatched dose comparisons to claim superiority over Wegovy and Ozempic. Novo is seeking an injunction and corrective advertisements.
Investors now turn attention to Novo Nordisk's upcoming second-quarter results, expected around early August. According to Fiscal AI data, the company is projected to report revenue of DKK 71.5 billion, down from DKK 76.9 billion in the prior-year quarter, with earnings per share of DKK 5.04 compared to DKK 5.96 a year earlier.
The company's share buyback program—approved for up to approximately $2.3 billion (DKK 15 billion) over 12 months beginning February 4, 2026—has provided some support, with roughly 25.9 million B shares repurchased for approximately $1.10 billion (DKK 7.16 billion) by July 24. NVO stock has declined 7% year-to-date.